Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women

Valasoulis, George; Pouliakis, Abraham; Michail, Georgios; Kottaridi, Christine; Spathis, Aris; Kyrgiou, Maria; Paraskevaidis, Evangelos; Daponte, Alexandros

doi:10.3390/cancers12051164

Cited by 29 publications

(34 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interest about the potential role of HPV adjuvant vaccination is confirmed by the “VIVA trial” [ 38 ], an ongoing RCT investigating about the possibility of post-surgical HPV vaccination in order to reduce vulvar and anal HSIL recurrence. The role of HPV vaccine in patients with prevalent infection is still controversial—a very recent article analysed this open question [ 39 ]. The study investigated the hypothesis that HPV vaccination administered in patients with low-grade cytology could prospectively alter HPV-related biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease

et al. 2021

View full text Add to dashboard Cite

Data suggest that adjuvant human papillomavirus (HPV)-vaccination in women treated for cervical HPV diseases reduces recurrent disease. This study investigates adjuvant HPV-vaccination and the rate of recurrence in women undergoing surgery for vulvar high-grade squamous intraepithelial lesions (HSIL). From January 2013 to April 2020, we enrolled 149 women in a prospective case-control study. The control group (NV-group) was treated by standard surgery alone, while the study group received adjuvant vaccination soon after surgery (V-group). A follow-up was performed by vulvoscopy and HPV test. Statistical analysis was performed by Fisher’s exact test. HSIL recurrence was observed in 24/76 (32%) patients in NV-group and in 8/42 patients (19%) of the vaccinated group. By analysing the recurrence rate related to the incident and reactivated latent HPV infection, we found a significant difference between (17/76) 22.3% in NV-group and (2/42) 4.8% in V-group (p = 0.01). A reduction of 78.5% in incident/reactivated HPV infections was demonstrated. Data results add to the current knowledge about the mechanism of post-surgical adjuvant HPV vaccination. Our prospective study is the first to document the vaccine clinical effectiveness in preventing “reactivation” of latent HPV infections. Quadrivalent HPV vaccine administered after the surgical treatment for vulvar HSIL appears to be useful in preventing recurrent disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Patients attending colposcopy clinics who have been vaccinated following a local cervical treatment [ 52 ] or in the context of the follow-up of established lesions [ 45 ] represent additional potential candidates for the assessment of urine HPV with tailored tests. The utilization of sensitive urine HPV assays as a test of cure following local treatments in the cervix is also an attractive potential option [ 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

“…The assessment of HPV-related biomarkers detection in vaccinated populations is a continuing challenge [ 45 , 46 ]. In the emerging field of monitoring the results of HPV vaccination, detecting HPV antibodies in urine represents an alternative promising approach for noninvasive sampling to monitor HPV antibody status in women participating in large epidemiological studies and HPV vaccine trials [ 47 ].…”

Section: Urine Hpv As a Proxy For Hpv Vaccination Coveragementioning

confidence: 99%

Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature

Daponte¹,

Michail

Daponte³

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Within the previous decades, following the widespread implementation of HPV-related biomarkers and computerization in liquid-based cytology, screening for lower genital tract malignancies has been optimized in several parts of the world. Many organized anogenital cancer prevention systems have reached a point at which efficacy is more a matter of population coverage and less of available infrastructures. Meanwhile, self-sampling modalities in which biologic material (vaginal secretions, urine, etc.) is obtained by the individual and not the clinician and subsequently undergoes examination for HPV biomarkers enjoy appreciating acceptance. Bygone the initial skepticism that vaginal or urine HPV represents “passenger” transient infections, extensive scientific work has been conducted to optimize high-risk HPV (hrHPV) detection from this “novel” biologic material. Nowadays, several state-of-the-art meta-analyses have illustrated that self-sampling techniques involving urine self-sampling represent a feasible alternative strategy with potentially enhanced population coverage possessing excellent performance and sensitivity. Recently published scientific work focusing on urine HPV was reviewed, and after a critical appraisal, the following points should be considered in the clinical application of hrHPV urine measurements; (i) use of first-void urine (FVU) and purpose-designed collection devices; (ii) using a preservation medium to avoid human/HPV DNA degradation during extraction and storage; (iii) using polymerase chain reaction (PCR) based assays, ideally with genotyping capabilities; (iv) processing of a sufficient volume of whole urine; and (v) the use of an analytically sensitive HPV test/recovery of cell-free HPV DNA in addition to cell-associated DNA.

show abstract

“…The implementation of HPV-related biomarkers to augment early detection and treatment of pre-invasive cervical lesions has constantly triggered the scientific efforts of our group [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. Extensive research has been published during the last decade adopting different approaches under the concept and umbrella of everyday clinical practice through pragmatic and feasibility studies [ 6 , 30 , 31 , 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

The Influence of Sexual Behavior and Demographic Characteristics in the Expression of HPV-Related Biomarkers in a Colposcopy Population of Reproductive Age Greek Women

Valasoulis

Pouliakis

Michail

et al. 2021

Biology

Self Cite

View full text Add to dashboard Cite

Despite the significant scientific evolution in primary and secondary cervical cancer prevention in the battle started by George Papanicolaou in the previous century, global cervical cancer mortality rates remain disappointing. The widespread implementation of HPV-related molecular markers has paved the way to tremendous developments in cervical cancer screening, with the transition from cytological approach to the more accurate and cost-effective HPV testing modalities. However, the academic audience and different health systems have not yet adopted a universal approach in screening strategies, and even artificial intelligence modalities have been utilized from the multidisciplinary scientific armamentarium. Combination algorithms, scoring systems as well as artificial intelligent models have been so far proposed for cervical screening and management. The impact of sexual lifestyle inherently possesses a key role in the prevalence of HPV-related biomarkers. This study aimed to investigate any possible influence of sexual behavior and demographic characteristics in the expression of HPV-related biomarkers in a colposcopy population from October 2016 to June 2017, and corroborated the determining role of age at fist intercourse; the older the age, the lower the probability for DNA positivity. Multivariate analysis illustrated additionally that a number of sexual partners exceeding 4.2 was crucial, with women with ≤5 partners being approximately four times less likely to harbor a positive HPV DNA test (p < 0.0001). Similarly, a reported partner change during the last year before HPV DNA assessment contributed to 2.5 times higher odds for DNA positivity (p = 0.0006). From this perspective, the further development and validation of scoring systems quantifying lifestyle factors that could reflect cervical precancer risk seems paramount.

show abstract

Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women

Cited by 29 publications

References 39 publications

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease

Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature

The Influence of Sexual Behavior and Demographic Characteristics in the Expression of HPV-Related Biomarkers in a Colposcopy Population of Reproductive Age Greek Women

Contact Info

Product

Resources

About